Endometriosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Description
Endometriosis Market Outlook
Thelansis’s “Endometriosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Endometriosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Endometriosis Overview
Endometriosis is a chronic, estrogen-dependent, systemic inflammatory disease characterized by the presence of endometrial-like tissue outside the uterine cavity. These ectopic lesions most commonly localize to the pelvic peritoneum, ovaries, and uterosacral ligaments, and are classified into three major phenotypes: superficial peritoneal endometriosis, ovarian endometriomas, and deep infiltrating endometriosis (DIE), which can involve organs such as the bowel and bladder. The disease is driven by cyclic, estrogen-mediated activity of ectopic tissue, leading to recurrent bleeding, chronic inflammation, fibrosis, and adhesion formation. Clinically, this manifests as severe chronic pelvic pain, dysmenorrhea, dyspareunia, and infertility, significantly impairing quality of life. Notably, disease severity does not consistently correlate with staging systems such as the ASRM classification, prompting a shift toward symptom-driven and imaging-supported diagnosis.
There is currently no definitive cure, and management is centered on long-term symptom control. Treatment approaches include surgical intervention for lesion excision and hormonal therapies aimed at suppressing estrogen production, such as progestins and GnRH antagonists (e.g., elagolix, relugolix). Despite available options, recurrence and suboptimal symptom control remain common, underscoring persistent unmet need.
Key Highlights
In the US, symptomatic cases are projected to increase from 4.41M in 2025 to 4.72M by 2035, reflecting steady growth (0.7% CAGR) driven by improved awareness and diagnosis.
The disease is associated with substantial diagnostic delays and heterogeneous presentation, complicating effective disease management.
Lack of curative therapies and high recurrence rates highlight a significant unmet need for more durable and targeted treatment options.
Market Overview
The Germany endometriosis market is projected to grow from $124M in 2025 to $414M by 2035, reflecting strong double-digit growth driven by uptake of novel hormonal therapies.
Market expansion is supported by:
Increasing adoption of oral GnRH antagonists and advanced hormonal treatments
Improved diagnosis and treatment rates
Despite moderate patient growth, market value is driven by chronic treatment duration and premium-priced therapies.
Future growth will depend on the development of disease-modifying therapies that provide sustained symptom relief and reduce recurrence rates.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
In-depth interviews with leading KOLs and payers
Physician surveys
RWE analysis for claims and EHR datasets
Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Key business questions answered:
How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
What is the 10-year market outlook for sales and patient share?
Which events will have the greatest impact on the market’s trajectory?
What insights do interviewed experts provide on current and emerging treatments?
Which pipeline products show the most promise, and what is their potential for launch and future positioning?
What are the key unmet needs and KOL expectations for target profiles?
What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
and more…
Country covered:G8 Markets
United States
EU5
France
Germany
Italy
Spain
U.K.
Japan
China
Thelansis’s “Endometriosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Endometriosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Endometriosis Overview
Endometriosis is a chronic, estrogen-dependent, systemic inflammatory disease characterized by the presence of endometrial-like tissue outside the uterine cavity. These ectopic lesions most commonly localize to the pelvic peritoneum, ovaries, and uterosacral ligaments, and are classified into three major phenotypes: superficial peritoneal endometriosis, ovarian endometriomas, and deep infiltrating endometriosis (DIE), which can involve organs such as the bowel and bladder. The disease is driven by cyclic, estrogen-mediated activity of ectopic tissue, leading to recurrent bleeding, chronic inflammation, fibrosis, and adhesion formation. Clinically, this manifests as severe chronic pelvic pain, dysmenorrhea, dyspareunia, and infertility, significantly impairing quality of life. Notably, disease severity does not consistently correlate with staging systems such as the ASRM classification, prompting a shift toward symptom-driven and imaging-supported diagnosis.
There is currently no definitive cure, and management is centered on long-term symptom control. Treatment approaches include surgical intervention for lesion excision and hormonal therapies aimed at suppressing estrogen production, such as progestins and GnRH antagonists (e.g., elagolix, relugolix). Despite available options, recurrence and suboptimal symptom control remain common, underscoring persistent unmet need.
Key Highlights
In the US, symptomatic cases are projected to increase from 4.41M in 2025 to 4.72M by 2035, reflecting steady growth (0.7% CAGR) driven by improved awareness and diagnosis.
The disease is associated with substantial diagnostic delays and heterogeneous presentation, complicating effective disease management.
Lack of curative therapies and high recurrence rates highlight a significant unmet need for more durable and targeted treatment options.
Market Overview
The Germany endometriosis market is projected to grow from $124M in 2025 to $414M by 2035, reflecting strong double-digit growth driven by uptake of novel hormonal therapies.
Market expansion is supported by:
Increasing adoption of oral GnRH antagonists and advanced hormonal treatments
Improved diagnosis and treatment rates
Despite moderate patient growth, market value is driven by chronic treatment duration and premium-priced therapies.
Future growth will depend on the development of disease-modifying therapies that provide sustained symptom relief and reduce recurrence rates.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
In-depth interviews with leading KOLs and payers
Physician surveys
RWE analysis for claims and EHR datasets
Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Key business questions answered:
How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
What is the 10-year market outlook for sales and patient share?
Which events will have the greatest impact on the market’s trajectory?
What insights do interviewed experts provide on current and emerging treatments?
Which pipeline products show the most promise, and what is their potential for launch and future positioning?
What are the key unmet needs and KOL expectations for target profiles?
What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
and more…
Country covered:G8 Markets
United States
EU5
France
Germany
Italy
Spain
U.K.
Japan
China
Table of Contents
153 Pages
- 1. Key Findings and Analyst Commentary
- 1.1 Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.
- 2. Disease Context
- 2.1 Disease definition, classification, etiology and pathophysiology, drug targets, etc.
- 3. Epidemiology
- 3.1 Key takeaways
- 3.2 Incidence / Prevalence
- 3.3 Diagnosed and Drug-Treated populations
- 3.4 Comorbidities
- 3.5 Other relevant patient segments
- 4. Market Size and Forecast
- 4.5 Key takeaways
- 4.6 Market drivers and constraints
- 4.7 Drug-class specific trends
- 4.8 Country-specific trends
- 5. Competitive Landscape
- 5.1 Current therapies
- 5.1.1 Key takeaways
- 5.1.2 Dx and Tx journey/algorithm
- 5.1.3 Key current therapies – profiles and KOL insights
- 5.2 Emerging therapies
- 5.2.1 Key takeaways
- 5.2.2 Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- 5.2.3 Notable early-phase pipeline
- 6. Unmet Need and TPP Analysis
- 6.1 Top unmet needs and future attainment by emerging therapies
- 6.2 TPP analysis and KOL expectations
- 7. Regulatory and Reimbursement Environments (by country and payer insights)
- 8. Appendix (e.g., bibliography, methodology)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
